Angelini Pharma – “CRDMO” The new business model for future of the (bio)pharma industry

e-version image

Click HERE to download the PDF


Today CDMOs face excellent growth opportunities in a pharmaceutical market environment where using outsourcing services is becoming the new norm. Indeed, the outlook for outsourcing is brighter than ever as ever more pharmaceutical and biotechnology firms continue to rely more heavily on external service providers for research, development and manufacturing of their own R&D pipeline and products portfolio. According to an analysis conducted by Grand View Research, the current outsourced market is estimated to be about $90 billion and is projected to grow at a healthy CAGR of about 7% to approximately $117.3 billion by 2023 and to represent about 30% of the overall manufacturing requirements.[1] The Big Pharma downsizing and the continued rise of small- and -med ... ...